These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477 [TBL] [Abstract][Full Text] [Related]
5. Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis. Yuan W; Li Y; Wang J; Li J; Gou S; Fu P Nephrology (Carlton); 2015 Jul; 20(7):459-66. PubMed ID: 25753148 [TBL] [Abstract][Full Text] [Related]
6. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Hocher B; Schwarz A; Reinbacher D; Jacobi J; Lun A; Priem F; Bauer C; Neumayer HH; Raschack M Nephron; 2001 Feb; 87(2):161-9. PubMed ID: 11244312 [TBL] [Abstract][Full Text] [Related]
7. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499 [TBL] [Abstract][Full Text] [Related]
8. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. Wenzel RR; Littke T; Kuranoff S; Jürgens C; Bruck H; Ritz E; Philipp T; Mitchell A; J Am Soc Nephrol; 2009 Mar; 20(3):655-64. PubMed ID: 19144760 [TBL] [Abstract][Full Text] [Related]
9. Endothelin A receptor antagonists in diabetic kidney disease. Georgianos PI; Agarwal R Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):338-344. PubMed ID: 28520568 [TBL] [Abstract][Full Text] [Related]
10. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. Dhein S; Hochreuther S; Aus Dem Spring C; Bollig K; Hufnagel C; Raschack M J Pharmacol Exp Ther; 2000 May; 293(2):351-9. PubMed ID: 10773002 [TBL] [Abstract][Full Text] [Related]
11. Potential new therapeutic agents for diabetic kidney disease. Turgut F; Bolton WK Am J Kidney Dis; 2010 May; 55(5):928-40. PubMed ID: 20138415 [TBL] [Abstract][Full Text] [Related]
13. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel? Ritz E; Wenzel RR J Am Soc Nephrol; 2011 Apr; 22(4):593-5. PubMed ID: 21415160 [No Abstract] [Full Text] [Related]
14. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease. Ortiz A; Fernandez-Fernandez B Clin J Am Soc Nephrol; 2021 Dec; 16(12):1775-1778. PubMed ID: 34853063 [No Abstract] [Full Text] [Related]